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57 ABSTRACT 
A wound dressing of the type having a water soluble 
plasma soluble self-supporting flexible body and which 
may be aerated and foamed. The flexible body is self 
adhering to the wound tissues and forms an artificial 
eschar with the moist elements at the situs of the 
wound. The flexible body is formed primarily from a 
water soluble dextran polymer. 
6 Claims, No Drawings 
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DRESSING AND METHOD FOR TREATING A 
WOUND 
This invention relates to a dressing for a lesion or 
wound and a method for the use thereof in treating the 
same. More particularly it relates to dressings of the 
type having a water and plasma soluble flexible body 
that is capable of forming an artificial eschar with the 
exudates issuing from a lesion to which the dressing is 
applied. The dressing may contain medicaments or 
therapeutic agents for beneficially treating the wound. 
The dressing sequentially dissolves in the tissue of the 
wound, thereby sequentially releasing medicaments in 
the wound tissue. . . . . 
U.S. Pat. No. 3,328,259 to Anderson, patented June 
27, 1967, describes dressings of the type provided by 
the present invention. The dressings in the Anderson 
patent are stated to be water and plasma soluble and 
when applied to a wound are capable of forming an 
artificial eschar to protect the same while gradually 
dissolving and releasing therapeutic agents. As de 
scribed in said patent such dressings have numerous 
advantages over previously used dressings. For exam 
ple, ordinary gauze type dressings become incorpo 
rated into the granulation tissue at the surface of the 
lesion so that the new healthy tissue may be pulled off 
when the dressing is removed. Ordinary dressings are 
undesirably bulky, have to be changed at frequent in 
tervals and cause an increase in maceration with subse 
quent prolongation of healing time. Occlusive dress 
ings, such as creams, lotions, ointments and the like, 
must be rubbed into the open lesion thereby producing 
pain. Also, removal of occlusive materials is difficult. 
Such materials are generally not satisfactory because 
they do not permit air contact with wounds and like 
ordinary dressings cause an increase in maceration of 
the healing tissue. s 
In contrast to ordinary gauze type dressings and oc 
clusive type dressings, the present flexible hydrophilic 
film is applied without inunction, is non-irritating to the 
lesion, is self-adhesive to the lesion, is easily removable 
by immersion for a few seconds in water or it may be 
left in place to be absorbed systemically, and excreted 
by the body. While being absorbed, therapeutic agents 
or medicaments may be gradually released to the 
wound. The present type of dressing is thus a highly 
efficient dosage form for local therapy. 
While the dressing provided by the Anderson patent, 
in common with the present dressing, provides many of 
these advantages over the older prior art, the principal 
component of the present dressing provides significant 
advantages over, the materials used in the Anderson 
patent. Specifically the Anderson dressing is formed 
from certain water and plasma soluble cellulose deriva 
tives. In the instant invention, the dressing is formed 
from water and plasma soluble dextran polymers in 
which the dextran is present in a sufficient amount to 
cause the flexible body formed therewith to form an 
artificial eschar with the moist elements at the situs of 
the wound. The dextran based flexible bodies of the 
present invention exhibit significant improvements in 
increased rates of solution in water and plasma in com 
parison with the flexible body dressings of the Ander 
son patent. For example, the Anderson dressings as 
disclosed in Example 4 of the Anderson patent require 
1 minute and 10 seconds to dissolve in water. Dressings 
of the present invention are capable of dissolving in 30 




The dextran polymers of this invention are also ad 
vantageous in that they are generally available in a 
higher degree of purity than the cellulose materials of 
the prior art. Considering the application of the dress 
ing produced therewith and the fact that it dissolves 
into the wound to be carried systemically points up the 
significance of such a fact. Along the same lines, the 
present dextran polymers are fully compatible with the 
human body and present substantially no question of 
toxicity or other potential health hazards. The cellulose 
materials of the prior art are not known to be com 
pletely free from any such complications. Moreover, 












Anderson patent is not equally applicable to the extent 
that it suggests the use of sodium salts of cellulose deriv 
atives in the formation of its dressing. In certain in 
stances the systemic incorporation of the sodium cellu 
lose salts may introduce an undesirable excess of so 
dium in the body, taxing the body salt balance and 
inducing stress. 
In the broad aspects of the present invention, the 
general considerations described in the Anderson pa 
tent are applicable except of course for the use of the 
instant dextran polymers instead of cellulose deriva 
tives. In general the dextran polymer of the present 
invention will have an average molecular of about 
40,000 to 100,000. For example, dressings made from 
specific dextran polymers having an average molecular 
weight of 40,000, 70,000 and 86,900 have been found 
to be satisfactory. 
Preferably before use the formulation is reduced in 
moisture content so that the water is about 5-15% by 
weight of the dressing and the dextran polymer is about 
60-90% by weight of the dressing thereby providing a 
solid self-supporting film-like material of suitable thick 
ness. The dextran polymer is in an integral porous non 
discrete form. The preferred form of the present body 
is as an aerated foam. This provides oxygen to the 
wound and also is more rapidly soluble compared with 
a non-foamed embodiment. . 
Where an aerated foam is the desired form, it is bene 
ficial to include a surfactant in the formulation as a 
foaming agent. The surfactant also serves as an emulsi 
fier. Such surfactant may be anionic, cationic, nonionic 
or amphoteric and is selected for its compatability and 
stability, with the other components in the formulation. 
Examples of suitable surfactants are the ionic dioctyl 
sodium sulfosuccinate, the nonionic polyoxyethylene 
sorbitan monolaurate, and the amphoteric commercial 
material available under the name Miranol 2MCA 
Modified. 
As before the film or body of the present invention 
may include antiseptics, steroids, germicidals, anesthet 
ics, antibiotic materials and the like to minimize infec 
tion, pain and generally promote healing. Such materi 
als are herein referred to generally as medicaments. 
Specifically it is contemplated to include mafenide or 
povidone iodine into the present dressing body or film. 
In other embodiments silver salts such as silver nitrate, 
silver sulfadiazine, gentamicin and salts thereof and 
local anesthetics such as lidocaine, benzocaine and 
salts thereof are specifically contemplated. Such medi 
caments are advantageously applied to wounds through 
the present dressing as distinguished from the dosage 
forms previously used therefor. 
As before some residual moisture on the order of 
5-15% by weight is desired so as to avoid a film that is 
either too brittle or too soft when outside of these lim 
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its. To this end plasticisers or humectants such as glyc 
erin, sorbitol, propylene glycol and the like may be 
included in the formulation. Optional ingredients may 
include anti-oxidants and stabilizers for examples. Also 
consistent with prior procedures, the present dressing 
may be sterilized as with ethylene oxide, CO, or the 
like. Packaging is preferably in air proof and moisture 
proof material. 
The following examples will illustrate the invention; 
EXAMPLE 1 
As a typical solution for the preparing of hydrophilic 
aerated dry films of this invention, take 16 grams of 
dextran AMW 70,000 and dissolve it in 73.4 grams of 
water at 50-70°C. To this solution, add 10.4 grams of 
sorbitol solution and 0.2 grams of Miranol 2MCA Mod 
ified. After whipping the film forming solution for 
10-15 minutes, the resultant foam may be spread to a 
uniform depth onto a Teflon coated drying surface and 
dried at 50-60°C to a moisture content of 5-15 per 
cent. Such a film is aerated and one square inch thereof 
dissolves in 0.1 ml. of water at room temperature in less 
than 30 seconds. 
*Average molecular weight 
EXAMPLE 2 
Take 20 grams of dextran AMW 86,900 and together 
with 8 grams of polyoxyethylene sorbitan monolaurate, 
16 grams of glycerin, and an amount of mafenide ace 
tate equivalent to 8.5 percent, by weight, of the dry 
film, and dissolve these in approximately 50 grams of 
water. After aerating the film forming solution by whip 
ping with a mixer, the resultant foam is cast, dried, and 
cut to appropriate size. 
EXAMPLE 3 
Take 18 grams of dextran AMW 40,000, 10.4 grams 







cinate, and dissolve these in approximately 70 grams of 0 
water. In addition, silver salts, such as silver nitrate and 
silver sulfadiazine, may be added to the film forming 
solution to provide their therapeutic effects. 
EXAMPLE 4 
Composition of film forming solution: 
Gms. 
Povidone Iodine 2.4 
Preservative 0.2 
Glycerin 0.5 
Sorbitol Solution 2.0 
Tween 20 1.0 
dextran AMW 86,900 77.9 









Povidone fodine 2.4 
Preservative 0.2 
Glyccrin 0.5 
Sorbitol Solution 2.0 
Tween 20 2.0 
dextran AMW 86,900 16.0 
Water 2.4 
EXAMPLE 5 
G m S 
Lidocaine Hydrochloride 




The above solution may be packaged in a pressurized 
aerosol utilizing suitable propellants. In this manner, 
the hydrophilic foam may be generated immediately 
prior to use by actuating the aerosol. 
EXAMPLE 6 
Gms. 
Dextran AMW 86,900 20.0 
Sorbitol Solution 2.6 
Water 77.4 
The above film forming solution comprises a formula 
tion to be used in preparing a non-aerated film for use 
as skin grafting material. 
What is claimed is: 
1. In a wound dressing of the type having a water 
soluble solid, self-supporting flexible body consisting 
essentially of a film-forming polymer in integral non 
discrete form in an amount sufficient to form an artifi 
cial eschar with the moist elements at the situs of the 
wound, the improvement in which said film-forming 
polymer is a plasma and water soluble dextran polymer 
having an average molecular weight of about 40,000 to 
about 100,000. 
2. The improvement in accordance with claim 1 
wherein said dextran body is porous. 
3. The improvement in accordance with claim 1 
wherein said dextran polymer is about 60-90% by 
weight of said flexible body. 
4. The improvement in accordance with claim 1 
wherein said flexible body contains about 5-15% by 
weight of water. 
5. The improvement in accordance with claim 1, 
wherein said flexible body contains medicaments pre 
selected to treat the wound to be covered by said flexi 
ble body. 
6. The improvement in accordance with claim 1 
wherein said flexible body is in the form of an aerated 
foam. 
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